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In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric 
acid combination were compared using metabolomics analyses. Men and women with combined 
hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-
density lipoprotein-cholesterol targets, but had triglyceride and high-density lipoprotein-cholesterol 
levels ≥150 mg/dL and <50 mg/dL, respectively, were randomized to receive atorvastatin 20 mg or 
atorvastatin 10 mg/fenofibric acid 135 mg for 12 weeks. Metabolite profiling of serum was performed 
and changes in metabolites after drug treatment in the two groups were compared. Analysis was 
performed using patients’ samples obtained before and after treatment. Of 89 screened patients, 
37 who met the inclusion criteria were randomized, and 34 completed the study. Unlike that in the 
dose-escalation group, distinct clustering of both lipid and aqueous metabolites was observed in the 
combination group after treatment. Most lipid metabolites of acylglycerols and many of ceramides 
decreased, while many of sphingomyelins increased in the combination group. Atorvastatin dose 
escalation modestly decreased lysophosphatidylcholines; however, the effect of combination therapy 
was variable. Most aqueous metabolites decreased, while l-carnitine remarkably increased in the 
combination group. In conclusion, the atorvastatin/fenofibric acid combination induced distinct 
metabolite clustering. Our results provide comprehensive information regarding metabolic changes 
beyond conventional lipid profiles for this combination therapy.
Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, is frequently used with statins 
to treat patients with dyslipidaemia and cardiovascular risk1,2. Further, fenofibrate has been reported to have ben-
eficial effects against microangiopathy in diabetic individuals. For example, fenofibrate slowed the progression 
of diabetic retinopathy3 and impairment of renal function4. In addition, some recent consensuses recommend 
the prescription of fenofibrate based on cardiovascular benefits demonstrated in populations with atherogenic 
dyslipidaemia5,6.
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A major biological role of PPARα agonist altering lipoprotein metabolism, resulting in enhanced production 
of apolipoprotein A1, reduced production of very low-density lipoproteins, increased lipolysis of triglycerides, 
and clearance of low-density lipoproteins7. In addition, PPARα agonists are known to modulate a large number 
of target genes that are involved in lipid transport, acyl-CoA metabolism, β-oxidation, ketogenesis, lipogenesis, 
lipolysis, lipoprotein metabolism, bile transport, glucose metabolism, amino acid metabolism, and inflamma-
tion8,9. Furthermore, it has been reported that PPARα activation decreases steatosis and chronic inflammation of 
liver10. Since PPAR agonists, including α isotype, display various metabolic effects, targeting PPARs in metabolic 
disorders is still a promising approach for metabolic disorders11.
Since metabolomics analysis techniques have been introduced, several studies have evaluated metabolic 
changes accompanying lipid modifying therapy. However, most of these studies examined changes in selected 
metabolites after a single drug treatment12,13.
The aim of the current study was to compare the metabolic effects of two lipid-modifying regimens. We exam-
ined whether dose escalation of atorvastatin and atorvastatin/fenofibric acid combination have differential met-
abolic effects. In addition to conventional lipid parameters, lipid and aqueous metabolites were comprehensively 
analysed using a metabolomics approach. In real-world clinical practice, patients with atherogenic dyslipidaemia 
are basically prescribed a statin, and a part of them are additionally prescribed a fibrate. Accordingly, a metabolic 
comparison of the two approaches (escalation or combination) in patients already taking statins is more helpful 
from a practical point of view. Our target regimens were determined considering this clinical background.
Results
Patient characteristics. A total of 89 patients were initially screened. After a 4-week run-in period, 52 indi-
viduals who did not meet the lipid criteria were excluded and 37 patients were randomized (19 to the dose-esca-
lation group and 18 to the combination group). Three participants dropped out during the trial and 34 completed 
the whole study (Supplementary Fig. S1). The study began in August, 2013 and ended in October 2015. Clinical 
characteristics of the patients who completed the study are shown in Table 1. The mean age was 63 years; 9 (26%) 
were females; 11 (32%) were diabetic; and 21 (62%) had coronary artery disease. The mean pre-randomized 
LDL-C level was 81 mg/dL. Baseline characteristics of the two groups were not different except for high density 
lipoprotein-cholesterol (HDL-C) levels, which were lower in the combination group. There was no harm or unin-
tended effect in each group.





(n = 16) p
Age, years 60.5 ± 8.3 64.4 ± 6.5 0.14
Female (%) 4 (22) 5 (31) 0.84
Medical history (%)
Diabetes mellitus 7 (39) 4 (25) 0.62
Hypertension 10 (56) 14 (88) 0.10
Current smoker 7 (39) 4 (25) 0.62
Coronary artery disease 12 (67) 9 (56) 0.21
Body mass index, kg/m2 25.8 ± 2.8 25.8 ± 2.3 0.98
Laboratory values
TC, mg/dL 159 ± 24 158 ± 27 0.93
TG, mg/dL 225 (179, 295) 248 (204, 299) 0.67
HDL-C, mg/dL 38.9 ± 4.8 35.1 ± 5.2 0.03
LDL-C, mg/dL 80 ± 20 82 ± 20 0.85
ApoB, mg/dL 89 ± 16 87 ± 17 0.70
ApoA1, mg/dL 129 ± 22 119 ± 16 0.14
ApoB/A1 0.65 (0.61, 0.73) 0.74 (0.66, 0.79) 0.12
Medications (%)
β-blockers 10 (56) 7 (44) 0.73
Calcium channel blockers 6 (33) 10 (63) 0.18
ACE inhibitors or ARBs 10 (56) 13 (81) 0.22
Diuretics 5 (28) 3 (19) 0.83
Antiplatelet agents 15 (83) 10 (63) 0.33
Table 1. Baseline characteristics of the study population whose metabolites were analysed. Values are presented 
as number (%), mean ± standard deviation, or median (interquartile range); TC: total cholesterol; TG: 
triglyceride; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; apo: 
apolipoprotein; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker.
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Multivariate analysis of lipid metabolites. To compare the effect of two regimens, multivariate analysis 
was applied to UPLC/Q-TOF-MS data of the lipid extracts. PCA scatter plots derived from lipid extracts did not 
show a clear separation between the two groups before or after drug treatment in both positive and negative ESI 
modes (Supplementary Fig. S2A,B). In contrast, using 3D plots, lipid metabolites from the combination group 
only after treatment clustered well (Supplementary Fig. S3A,B). QC samples (pooled from every patient sample 
at consistent intervals) were analysed. QC samples clustered well within each PCA scatter plot, demonstrating 
reproducibility of the instrument. Scatter plots of lipid metabolites using PLS-DA, a supervised method, showed 
distinctively discriminated clustering patterns after combination therapy within the positive (R2X = 0.299, 
R2Y = 0.274, Q2 = 0.081) and negative (R2X = 0.199, R2Y = 0.340, Q2 = 0.071) modes (Fig. 1A,C). A clear separa-
tion before and after combination therapy was observed in the PLS-DA scatter plots in both positive (R2X = 0.547, 
R2Y = 0.991, Q2 = 0.661) and negative (R2X = 0.283, R2Y = 0.863, Q2 = 0.589) modes (Fig. 1B,D). In the PLS-DA 
plot, each symbol represents the metabolic pattern of each individual. In Fig. 1A,C, plots of combination group 
after treatment (▲) clustered on the left of PLS1 axis, indicating that combination group after treatment had dif-
ferent metabolic pattern than other groups. Likewise, a clear separation between two groups on the PLS1 axis in 
Fig. 1B,D indicates metabolic change in combination group after treatment. However, no separation was observed 
in the PLS-DA plots before and after treatment in the dose-escalation group. These results suggest that appreci-
able changes in lipid metabolites were associated with the combination rather than dose-escalation treatment.
Figure 1. Partial-least-square discrimination analysis (PLS-DA) scatter plots of serum lipid metabolites in the 
dose-escalation and combination groups. Ultra-performance liquid chromatography quadruple time of flight 
mass spectrometry (UPLC/QTOF MS) spectra in the positive (A,B) and negative modes (C,D) are shown. 
Data from the dose-escalation and combination groups before and after drug treatment are displayed in (A,C), 
whereas data from the combination group only are presented in (B,D). □: dose-escalation, before; ■: dose-
escalation, after; △: combination therapy, before; ▲: combination therapy, after.
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Significant changes in lipid metabolites. To understand and determine the contribution of significant 
lipid metabolites associated with the changes after combination therapy, we performed a PLS-DA to observe the 
distinct discriminations in the plot. Significantly different metabolites in the combination group were identified 
using variable important projection (VIP) >1 and p < 0.05 as selection criteria. Selected metabolites are listed 
according to their categories, including free fatty acids (FFA), acylcarnitines, cholesterol esters, LPCs, lysophos-
phatidylethanolamines, lysophosphatidylamines, phosphatidylamines, phosphatidylcholines, phosphatidyleth-
anolamines, phosphatidylinositols, sphingomyelins, ceramides, diacylglycerols, and triacylglycerols. The most 
remarkable lipid metabolite data involved diacylglycerols and triacylglycerols, which predominantly decreased 
regardless of the degree of chain length or saturation. Diacylglycerols and triacylglycerols decreased further in the 
combination group. In addition, the level of numerous ceramides decreased, and sphingomyelin levels increased 
after combination therapy (Fig. 2 and Supplementary Table S3); however, the changes in some ceramides and 
sphingomyelins did not follow the overall trend observed in the respective categories. (Fig. 2). Further, FFAs 
increased in the combination group (except FFA 22:5), while the fold change in FFAs showed a reverse pattern 
in the escalation group. The escalation group showed a modest decrease in LPCs; however, changes in LPC after 
combination therapy were variable (Supplementary Table S3).
Multivariate analysis of aqueous metabolites. Similar to the lipid metabolite data, PCA scatter plots 
derived from aqueous extracts did not show distinct separation patterns before and after drug treatment in 
either group in both positive and negative ESI modes (Supplementary Fig. S2B,D). When the PCA scatter plots 
were visualized in 3D, aqueous metabolites seemed to cluster after combination therapy (data not shown). To 
exclude the possibility of any artificial influence on reliability and precision, we also analysed QC samples; results 
showed that reproducibility of the instrument was respectable. No significant changes in the amount or class 
of metabolites were observed, except for the comparison data before and after combination therapy (data not 
Figure 2. Lipid metabolite changes in the dose-escalation and combination groups. Lipid metabolite data are 
presented with a bar graph using fold changes after/before treatment. Gray and black bars indicate the escalation 
and combination groups, respectively. Changes were significant for all metabolites of combination group and nine 
(FFA 22:5, DG 32:0, DG 34:1, PC 42:11, PI 32:1, PI 34:1, PI 36:4, TG 42:1, and TG 64:10) of dose-escalation group.
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shown). PLS-DA models of aqueous metabolites showed unique clustering patterns in the positive (R2X = 0.163, 
R2Y = 0.318, Q2 = 0.146) and negative (R2X = 0.256, R2Y = 0.313, Q2 = 0.154) modes after combination therapy 
only (Fig. 3A,C). We compared metabolites before and after each treatment to figure out differential changes. 
PLS-DA plots of the combination group showed noticeable separations before and after treatment both in the 
positive (R2X = 0.216, R2Y = 0.933, Q2 = 0.587) and negative (R2X = 0.368, R2Y = 0.996, Q2 = 0.885) modes 
(Fig. 3B,D), whereas similar results were not observed for the escalation group.
Changes in significant aqueous metabolites and acylcarnitine quantitative data. Based on the 
same criteria used to select lipid metabolites, 44 aqueous metabolites were identified as significantly changed after 
combination therapy. The metabolites are presented according to the following categories: amino acids, organic 
acids, fatty acids, bile acids, carnitine and its derivatives, and purine and other metabolites. Most of the aqueous 
metabolites decreased; however, carnitine and acylcarnitine increased after combination therapy (Fig. 4A and 
Supplementary Table S4). To confirm the remarkable changes in carnitine and its derivatives, we analysed serum 
from the study patients using Triple Quad mass spectrometry. Three metabolites (carnitine, acetylcarnitine, and 
octanoylcarnitine) were analysed quantitatively. QC samples were consistently analysed to determine reproduc-
ibility. Calibration curves and each sample were analysed with three replicates. Each calibration curve for the 
quantitatively analysed metabolites showed 99.9% reliability (Supplementary Table 1). The amount of carnitine in 
Figure 3. Partial-least square discriminant analysis (PLS-DA) scatter plots of serum aqueous metabolites in the 
dose-escalation and combination groups. Ultra-performance liquid chromatography quadruple time of flight 
mass spectrometry (UPLC/QTOF MS) spectra in the positive (A,B) and negative modes (C,D) are shown. Data 
from the dose-escalation and combination groups before and after drug treatment are displayed in A,C, whereas 
data from the combination group only are presented in (B,D). □: dose-escalation, before; ■: dose-escalation, 
after; △: combination therapy, before; ▲: combination therapy, after.
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serum from patients increased almost 3-fold after combination therapy, while acetylcarnitine and octanoylcarni-
tine increased 1.2- and 1.8-fold, respectively, after combination therapy (Fig. 4B).
Discussion
In the present study, the comparison was mainly of the added effect of fenofibric acid on atorvastatin versus 
dose-escalation of atorvastation. The major findings of this study include: (1) distinct clustering of both lipid and 
aqueous metabolites occurred after treatment in the atorvastatin/fenofibric acid combination group, whereas 
this phenomenon did not occur in the atorvastatin dose escalation group; (2) most lipid acylglycerol metabolites 
and many ceramides decreased in the combination group, while numerous sphingomyelins increased; (3) LPCs 
modestly decreased in the atorvastatin dose escalation group, whereas the effect of combination therapy on LPCs 
was variable; (4) most aqueous metabolites decreased in the combination group, while l-carnitine remarkably 
increased; and (5) changes in cholesterol and triglycerides differed between treatment groups, whereas changes 
in the apolipoprotein B/A1 (apoB/A1) ratio were similar between the two groups. These results provide compre-
hensive information regarding metabolic changes beyond conventional lipid profiles for statin/fenofibric acid 
combination therapy.
The concentration of ceramide metabolites tended to decrease after treatment in the combination group. This 
is consistent with a very recent report by Croyal et al.14, in which a global decrease in ceramides was shown after 
fenofibrate therapy using FIELD trial samples. The reduction in ceramides was possibly related to changes in 
synthesis in the circulation or in the liver where fenofibrate could affect rate-limiting steps of ceramide synthe-
sis. Although it is not certain, the reduction in ceramides could be indirectly attributable to the carrier effect of 
very low-density lipoprotein as modulated by fenofibrate. We observed an increasing trend in sphingomyelin 
metabolites after combination therapy. To date, the effect of fibrates on plasma sphingomyelin is not well known. 
Some studies have demonstrated that fenofibrate induces higher sphingomyelin on high-density lipoproteins in 
rabbits15 and humans16. Fenofibrate treatment enhanced the functional capacity of high-density lipoproteins in 
the former study, and the increase in sphingomyelin is a potential mechanism underlying the beneficial effect.
We found that the effects of the combination therapy on LPCs were variable; however, they were modestly 
decreased by higher dose of statin. LPC is produced from phosphatidylcholine of lipoproteins or cell membranes 
through the action of phospholipase A2, which is known to play a role in diverse biological processes includ-
ing anti-sepsis17. In a prior FIELD substudy, HDL lipidomic profiles associated with fenofibrate treatment were 
investigated. The authors found that LPC was diminished on HDL in their analysis13. We did not find similarly 
clear tendency of LPC after combination therapy. However, we cannot directly compare our results with those 
of above-mentioned study, since we analyzed LPC in serum rather than in HDL. In addition, phospholipase A2 
Figure 4. Aqueous metabolite changes in the dose-escalation and combination groups and quantitative analysis 
of carnitine and its derivatives in serum. Aqueous metabolite data are presented with a bar graph using fold 
changes after/before treatment (A), and the quantitative analysis data of carnitine and acylcarnitine (B) is 
shown. Changes were significant for all metabolites of combination group and one (acetyl carnitine) of dose-
escalation group.
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has been reported to have both pro- and anti-atherogenic properties18. Among LPCs assayed in humans, LPC 
16:0, 18:0, and 18:1 were shown to be associated with inflammation in atherosclerotic plaques19. However, clear 
differential changes in these species of LPC were not observed between the two regimens in the present study.
Of note, plasma l-carnitine clearly increased in the group receiving the combination therapy in our study. 
A previous study showed that activation of PPARα results in hepatic carnitine accumulation in mice. This 
phenomenon was mediated by means of enhanced carnitine biosynthesis20 and hepatic carnitine import21. 
Conversely, PPARα-knockout mice have 40–50% lower plasma and tissue levels of free carnitine22. Another study 
revealed that PPAR agonism with clofibrate increased intestinal carnitine absorption in rats23. Collectively, the 
above-mentioned studies may partly explain the elevation in l-carnitine after combination therapy in our study. 
Plasma l-carnitine levels have been reported to be predictive of greater cardiovascular risk. However, that finding 
was valid only in subjects with concurrently high trimethylamine-N-oxide (TMAO) levels24. It is not evident 
whether the increase in l-carnitine after combination therapy in our study has clinical relevance, attributable 
to a lack of TMAO data in this study. Dietary TMAO reportedly modulates cholesterol and sterol metabolism 
and suppresses reverse cholesterol transport24. In contrast, another study demonstrated that fenofibrate increases 
reverse cholesterol transport25. Furthermore, studies have revealed the beneficial properties of l-carnitine 
consumption or fish rich in TMAO, which contradicts studies reporting the harmful effects of l-carnitine26. 
Currently, caution is needed when interpreting data showing a rise in l-carnitine by regimen, including fenofibric 
acid, in terms of cardiovascular risk.
Not surprisingly, TG reduction and elevation of HDL-C were greater in combination group. The changes 
in the apoB/A1 ratio were comparable between the two groups. Rosenson et al.27 compared rosuvastatin and 
rosuvastatin/fenofibric acid at multiple doses and reported that the LDL-C lowering effects were greater in a 
high-dose statin group than in a low-dose statin/fenofibric acid group. Ballantyne et al.28 reported similar results 
in patients who received fenofibric acid in addition to statin therapy. In our current study, changes of LDL-C in 
dose-escalation group were quite variable, although they were significantly different from those in combination 
group. Determining the effects of a treatment regimen that affects multiple lipid parameters using measurements 
of cholesterol alone is inadequate. Instead, indexes, such as the apoB/A1 ratio, which reflect simultaneous changes 
in multiple lipoproteins1 and cardiovascular risk29 may be a more appropriate indicator of the efficacy of our treat-
ment regimens. However, we did not further investigate the findings of conventional lipid parameters, since their 
comparison was not the primary purpose of our study.
Our study has potential limitations. Although prescribing statins in drug-naïve patients can cause specific 
metabolic changes, the effects of escalating statin dose in patients with ongoing therapy may be less dramatic. We 
compared metabolic changes after using two different regimens in patients with ongoing lower-dose statin ther-
apy. Thus, less distinct clustering of metabolites after a dose-escalation of statins rather than combination therapy 
does not necessarily indicate that the former regimen has a smaller total metabolic influence. Our study provides 
useful information for adopting additional lipid modification policies. However, clinicians should consider the 
above-mentioned context.
Taken together, these data show that the statin/fenofibric acid combination induced a more distinct cluster-
ing of lipid and aqueous metabolites than the dose escalation of atorvastatin. Most lipid metabolites, including 
acylglycerols and ceramides, and aqueous metabolites decreased, whereas many sphingomyelins and l-carnitine 
increased after the combination therapy. Our study provides comprehensive information regarding metabolic 
changes beyond conventional lipid profiles after the statin/fenofibric acid combination therapy.
Methods
Study population. We initially screened men and women aged ≥20 years with triglyceride (TG) levels rang-
ing from 150 to 499 mg/dL and low-density lipoprotein-cholesterol (LDL-C) levels requiring lipid-lowering ther-
apy according to the 2004 National Cholesterol Education Program Adult Treatment Panel III guidelines30. After 
lifestyle modification and pharmacologic treatment with atorvastatin 10 mg for more than 4 weeks, individuals 
who met all the following criteria were enrolled: TG levels 150–499 mg/dL; HDL-C <50 mg/dL; and LDL-C levels 
<100 mg/dL in patients with coronary heart disease or its equivalent, including diabetes mellitus, or LDL-C levels 
<130 mg/dL in all other patients. Criteria for exclusion included a history of cerebrovascular or cardiovascular 
events in the past 3 months, uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥110 mmHg), uncon-
trolled diabetes mellitus (haemoglobin A1c levels >9%), serum creatinine or transaminase >2× the upper limit 
of normal, gall bladder disease, thyroid dysfunction, heavy alcohol drinking, infection, acute or chronic inflam-
matory disease, cancer, pregnant or breast feeding women, history of adverse events associated with test drugs, or 
refusal of enrolment. There was no sufficient data for sample size calculation. We referred to best available studies 
similar to our design and decided to enroll at least 12 to 17 subjects in each group. All participants provided 
written informed consent.
Study design. This study was a sub-study of a main trial, and we applied the protocol used in the main study 
(ClinicalTrials.gov number, NCT 01974297, registered 01/11/2013). This sub-study was a 12-week, randomized, 
open-label, multicentre study conducted at five sites in Korea. The study protocol conforms to ethical guidelines 
of the 1975 Declaration of Helsinki and was approved by the institutional review board (IRB) at each centre: 
IRB, Clinical Trial Center Severance Hospital, Seoul, Korea, IRB of Chungnam National University Hospital, 
Daejeon, Korea, IRB, Inje University Ilsan Paik Hospital, Goyang, Korea, IRB, Seoul National University Hospital 
Biomedical Research Institute, Seoul, Korea and IRB, Soonchunhyang University Hospital, Bucheon, Korea.
At the screening visit, patients were interviewed about their medical history and underwent a physical exam-
ination and laboratory assessment. Individuals who met the inclusion criteria after treatment with atorvastatin 
10 mg were randomly assigned to receive one of two regimens: atorvastatin 20 mg (Newvast; Hanmi Pharm Co. 
Ltd., Seoul, Korea) (dose-escalation group) or atorvastatin 10 mg (Newvast) plus fenofibric acid 135 mg (Fenocid; 
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Hanmi Pharm Co. Ltd.) (combination group). Sequentially numbered containers provided by AMD Korea 
(Seoul, Korea) were used for random allocation. All subjects in the five centers were assigned by block randomi-
zation. The study patients were instructed to take medications in the morning. Those in combination group took 
both components at the same time. Participants were followed up at the end of weeks 6 and 12 for tolerability and 
efficacy assessments.
Fasting blood samples were collected at randomization and at the end of week 12 of drug treatment. 
Laboratory values including lipid profiles were measured at these time points. Samples were analysed within 4 h 
of collection by a local laboratory that was certified by the Korean Society of Laboratory Medicine.
Sample extraction. Serum samples (50 μL) were transferred to a 1.5-mL tube and vortexed with 550 μL 
CHCl3:MeOH = 2:1 for 1 min. After adding 100 μL water, the samples were again vortexed for 1 min. The mixture 
was incubated at 4 °C for 10 min and centrifuged for 10 min at 13,000 × g and 4 °C. The supernatant (aqueous 
extract) was transferred into a 1.5-mL Eppendorf tube and dried using a vacuum concentrator. The solution under 
pellet (lipid extract) was transferred to a 1.5-mL Eppendorf tube and evaporated under a stream of nitrogen. For 
the ultra-performance liquid chromatography quadruple time of flight mass spectrometry (UPLC/Q-TOF-MS) 
analyses, aqueous extracts were diluted with an acetonitrile:water mixture (3:1, v/v) and lipid extracts were 
diluted with an isopropanol:acetonitrile:water mixture (2:1:1, v/v/v) and transferred into vials for analysis.
UPLC/Q-TOF-MS analysis for lipid and aqueous metabolites. Liquid chromatography-electrospray 
ionization–tandem MS analyses of lipid extracts and aqueous extracts were performed on a triple TOF™ 5600 
MS/MS system (Sciex, Concord, ON, Canada) combined with a UPLC system (Waters, Milford, MA, USA). Lipid 
extracts were separated on an Acquity UPLC BEH C18 column (2.1 × 100 mm with 1.7-μm particles; Waters), 
whereas aqueous extracts were separated on a SeQuant® ZIC® hydrophilic interaction liquid chromatography 
column (2.1 × 100 mm with 3.5-μm particles) (Merck Korea, Incheon, Korea).
The binary gradient system for lipid extracts comprised 10 mM ammonium acetate in an acetonitrile:water 
mixture (40:60, v/v; solvent A) and 10 mM ammonium acetate in an acetonitrile:isopropanol mixture (10:90, 
v/v; solvent B); for aqueous extracts, 0.1% formic acid with 10 mM ammonium acetate in an acetonitrile:water 
mixture (95:5, v/v; solvent A) and 0.1% formic acid with 10 mM ammonium acetate in an acetonitrile:water mix-
ture (50:50, v/v; solvent B) were used. The sample injection volume was 5 μL, and the partial loop mode for both 
positive and negative ionization polarity modes was used. MS with chromatography is used to detect metabolites 
that are positively or negatively charged by their ionization characteristics. Metabolites, such as fatty acids and 
organic acids, are covered in negative modes, while triacylglycerols and diacylglycerols are covered in positive 
modes.Pooled quality control (QC) samples were measured for data reproducibility.
Quantitative analysis of metabolites. To perform quantitative analysis, ultra-high performance liq-
uid chromatography triple quadrupole mass spectrometry analyses of aqueous extracts, including carnitine, 
acetyl-carnitine, and ocatonyl-carnitine, were performed on an Agilent 1290 Infinity LC and an Agilent 6495 
Triple Quadrupole MS system equipped with an Agilent jet stream ESI source (Agilent Technologies, Palo Alto, 
CA, USA). Separations and the binary gradient system were identical to the UPLC/Q-TOF-MS analysis of the 
aqueous extracts. The column effluent was introduced into a triple quadrupole mass detector operating in a 
positive or negative ESI mode. Samples were analysed via the simple reaction monitoring mode for transition of 
the parent ion to the product ion. Characteristics of multiple reaction monitoring (MRM), calibration curve, and 
accuracy are shown in Supplementary Table 1.
Pre-processing of lipid and aqueous UPLC-Q/TOF-MS data. UPLC/Q-TOF-MS spectral data were 
analysed using MarkerViewTM (Sciex, Concord, ON, Canada), which was used to find peaks, perform the align-
ment, and generate peak tables of m/z and retention times. Spectra were normalized to the total spectral area. To 
identify reliable peaks and decrease instrumental bias, features with coefficients of variation below 20 in qual-
ity control samples were selected. Lipids were putatively identified by comparing the experimental data against 
various lipid metabolite databases, including LIPID MAPS (www.lipidmaps.org), Metlin (metlin.scripps.edu), 
and Human Metabolome (www.hmdb.ca) databases. Isotope pattern matching and fragment patterns (MS/MS 
spectra) were similarly used to identify lipid metabolites. Lysophosphatidylcholine (LPC), phosphatidylcholine, 
and sphingomyelin species showed distinct fragmentation patterns, including an abundant product ion of m/z 
184 in the positive ESI mode tandem mass spectra. Neutral loss fragments of m/z 141 were used to identify lys-
ophosphatidylethanolamine and phosphatidylethanolamine. Ceramide was analysed by means of neutral loss 
fragments of 277, 185, and 264. Peak findings, as well as alignment and filtering of raw data were performed using 
MarkerView Version 1.2.1.1 (Sciex, Concord, ON, Canada).
Data collection parameters in peak findings were set as follows: mass range, m/z 50–1500; retention time 
range, 0.2–21 (18 for aqueous MS data) min; subtraction offset, 5 scans; subtraction multiplier, 1.5; minimum 
spectral peak width, 1 ppm; and retention time peak width, 5 scans. For peak alignment, retention time and mass 
tolerances were set at 0.1 min and 10 ppm, respectively. The intensity threshold for peak filtering was set at 10, and 
peaks detected in fewer than five samples were removed. Peak area matrixes were normalized by total sum area 
normalization to remove systematic variation among the samples.
Two processes were used to decrease instrumental bias and identify reliable peaks: background peak ions 
in raw data were eliminated using a ratio of peak QC intensity to blank intensity (QC/blank >3), and peaks 
exhibiting a large variation in QC were eliminated (coefficient of variation (CV) >20%). All variables were ten-
tatively identified based on free accessible metabolite databases such as Mass Bank (http://www.massbank.jp), 
Metlin (http://metlin.scripps.edu/), and LIPID MAPS (http://www.lipidmaps.org) and were compared to ana-
lysed standards.
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For quantification analysis, calibration curves were constructed by plotting the peak area/internal stand-
ard peak ratio versus the concentration of each sample using MassHunter quantitative analysis for Triple Quad 
(Agilent Technologies).
Statistical analysis. Clinical and laboratory variables were compared using the student’s t test or chi-square 
test. A paired t test was used to compare the parameters before and after drug treatment. For the variables showing 
skewed distribution, the Wilcoxon signed-rank test for the median was used. All the analyses used two-tailed tests 
with a significance level of 0.05. Statistics for the social sciences version 17.0 (SPSS Inc., Chicago, IL, USA) was 
used for the analyses. For the UPLC-Q/TOF-MS data, chemometric methods were used to characterize and visu-
alize differences and similarities among the different groups and samples. Principal component analysis (PCA) is 
an unsupervised method that analyses samples in the absence of information about the samples. Prior to PCA, all 
variables obtained from UPLC-MS data sets were scaled to unit variance (UV). Partial least squares-discriminant 
analysis (PLS-DA) was used to maximize class discrimination. PLS finds a linear regression model by projecting 
the predicted and observed variables to a new space. X and Y data are projected to new spaces, and PLS-DA is a 
variant method used when Y variable is categorical. The primary goal of PLS is to identify class differences from 
a multivariate dataset. A class refers to biologically relevant classification, such as humans treated with specific 
drug31. For example, metabolomics studies using this statistical method were performed to determine metabolite 
levels in bone32, heart, and serum of mice33, and aortic tissues of humans34. PLS-DA regression models are inter-
preted by R and Q square values. R value indicates fitness of model, and a value close to one means good fitness. 
Q value indicates goodness of prediction and a value over 0.5 means good prediction. PCA and PLS-DA were 
conducted using SIMCA-P+ (ver. 12.0; Umetrics, Umea, Sweden). VIP score is the projection of each variable, 
and it is also the selection criterion for important variable in a PLS model. Variables with scores over or close to 
one are considered important in a given model.
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